Perioperative Finotonlimab Plus Chemotherapy in Untreated Stage II HNSCC

This multicenter, randomized, open-label, parallel-controlled clinical trial aims to evaluate the efficacy and safety of surgery combined with postoperative chemoradiotherapy versus finotonlimab plus induction chemotherapy followed by postoperative finotonlimab maintenance therapy in patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).

NCT Number	NCT07751276
Lead Sponsor	Yanjie Zhang, MD
Conditions	Head and Neck Squamous Cell Carcinoma HNSCC
Enrollment	142 participants
Start Date	2026-08-01
Primary Completion	2029-12-31 (estimated)
Study Completion	2032-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-07